DK2951309T3 - Forøget transgenekspression og -processering - Google Patents

Forøget transgenekspression og -processering Download PDF

Info

Publication number
DK2951309T3
DK2951309T3 DK14708935.3T DK14708935T DK2951309T3 DK 2951309 T3 DK2951309 T3 DK 2951309T3 DK 14708935 T DK14708935 T DK 14708935T DK 2951309 T3 DK2951309 T3 DK 2951309T3
Authority
DK
Denmark
Prior art keywords
leu
mar
lys
ala
glu
Prior art date
Application number
DK14708935.3T
Other languages
English (en)
Inventor
Fourn Valérie Le
Nicolas Mermod
Alexandre Regamey
Montse Buceta
Déborah Ley
Niamh Harraghy
Kaja Kostyrko
Pierre-Alain Giro
David Calabrese
Original Assignee
Selexis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selexis Sa filed Critical Selexis Sa
Application granted granted Critical
Publication of DK2951309T3 publication Critical patent/DK2951309T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/90Vectors containing a transposable element
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/46Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Claims (14)

1. Rekombinant nukleinsyremolekyle omfattende: en 5' og en 3' transposon-specifik inverteret terminal repeat (ITR), mindst én nukleinsyresekvens, der koder for et TEP (transgene expression processing)-protein eller en TEP-funktionel RNA, placeret mellem 5' og 3' ITR'ene, og som er under en promoters kontrol, og Mindst ét MAR (matrix attachment region)-element placeret mellem 5' og 3' ITR'ene; hvor TEP-proteinet er en eller flere af følgende aminosyresekvenser af proteiner fra proteinsekretionsvejen: hSRP14 med SEQ ID NO: 13, hSec61al med SEQ ID NO: 15, hSec6ip med SEQ ID NO: 17, hSec61y med SEQ ID NO: 19, hSRP54 med SEQ ID NO: 21, hSRP9 med SEQ ID NO: 23, hSRPRa med SEQ ID NO: 25, hSRPP med SEQ ID NO: 27 og hCANX med SEQ ID NO: 29 og aminosyresekvenser med mere end 80 %, 90 %, 95 % eller 98 % sekvensidentitet med de angivne sekvenser, hvilken TEP-funktionel RNA, fortrinsvis en miRNA eller en shRNA, interfererer med ekspressionen af ét protein i en rekombinationsvej, der er udvalgt fra Rad51, Rad51C, Rad51D, Xrcc2, Xrcc3, Rad52, Rad54, Brcal, Cyclin Dl, Bardi eller Mre 11, og hvor MAR-elementet er udvalgt fra SEQ ID NO: 1 (MAR 1-68), 2 (MAR 1_6), 3 (MAR X_S29), 4 (MAR S4), 5 (hønselysozym- MAR), eller er en konstrueret, særligt omarrangeret, sidestykke, der har mindst 80 %, 90 %, 95 %, 98 %, 99 % eller 100 % sekvensidentitet med en hvilken som helst af SEQ ID NO: 1 til 5, og hvor TEP'en eller den TEP-funktionelle RNA, der udtrykkes via nukleinsyremolekylet, og MAR-elementet er i stand til at øge ekspressionen af et transgen i en pattedyrcelle med mindst 10 %.
2. Rekombinant nukleinsyremolekyle ifølge krav 1, der endvidere omfatter mindst ét transgen, der er placeret mellem 5' og 3' ITR'ene, hvilket transgen er under en transgenpromoters kontrol.
3. Vektor omfattende det rekombinante nukleinsyremolekyle ifølge krav 1 eller 2.
4. Vektor ifølge krav 3, hvor vektoren omfatter et enkelt MAR-element eller to eller flere MAR-elementer, hvor elementet (elementerne) er placeret mellem 5' og 3' ITR'ene.
5. Vektor ifølge krav 3, hvor vektoren omfatter to MAR-elementer, hvor et første MAR-element er anbragt opstrøms for TEP'et eller den TEP-funktionelle RNA, og et andet MAR-element er anbragt nedstrøms for TEP'et eller den TEP-funktionelle RNA, hvor det første MAR-element omfatter et MAR l_6-element eller et element, der har mindst 80 %, 90 %, 95 %, 98 %, 99 % eller 100 % sekvensidentitet med SEQ ID NO. 2, særligt en omarrangeret MARs baseret på MAR 1-6, mere særligt elementer, der har mindst 80 %, 90 %, 95 %, 98 %, 99 % eller 100 % sekvensidentitet med SEQ ID NO 8 (MARs 1_6R2) og det andet MAR-element omfatter et MAR 1-68-element eller et element, der har mindst 80 %, 90 %, 95 %, 98 %, 99 % eller 100 % sekvensidentitet med SEQ ID NO. 1.
6. Vektor ifølge krav 3, hvor vektoren omfatter det enkelte MAR-element, hvor det enkelte MAR-element er anbragt nedstrøms for TEP'et eller den TEP-funktionelle RNA, hvor det enkelte MAR-element er et MAR 1-68- eller et MAR X-29-element eller et element, der har mindst 80 %, 90 %, 95 %, 98 %, 99 % eller 100 % sekvensidentitet med SEQ ID NO. 1 eller 3, særligt et omarrangeret MAR baseret på MAR 1-68 eller et MAR X-29, særligt et element, der har mindst 80 %, 90 %, 95 %, 98 %, 99 % eller 100 % sekvensidentitet med SEQ ID NO: 6, 7 eller 10 (MAR 1_68R, 1_68R2 eller X_29R3) eller 9, og fortrinsvis er et MAR X-29-element eller et element, der har mindst 80 %, 90 %, 95 %, 98 %, 99 % eller 100 % sekvensidentitet med SEQ ID NO. 3.
7. Fremgangsmåde til ekspression af et transgen og et TEP (transgene expression processing)-protein eller en TEP-funktionel RNA in vitro omfattende: tilvejebringelse af en rekombinant pattedyrcelle omfattende et transgen og indføring af en vektor ifølge et hvilket som helst af kravene 3 til 6 i den rekombinante pattedyrcelle, som udtrykker transgenet og TEP'et eller den TEP- funktionelle RNA, hvor TEP'et eller den TEP-funktionelle RNA, der udtrykkes via vektoren, eventuelt øger en ekspression af et transgen i pattedyrcellen med mindst 10 %, mindst 20 %, mindst 30 %, mindst 40 %, mindst 50 %, mindst 60 % eller mindst 70 %.
8. Fremgangsmåde ifølge krav 7, hvor vektoren omfatter et enkelt MAR X-29-element eller en nukleinsyresekvens med mindst 80 %, 90 %, 95 %, 98 %, 99 % eller 100 % sekvensidentitet med SEQ ID NO. 3, og hvor TEP'et eller den TEP-funktionelle RNA, der udtrykkes via vektoren, efter mere end 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 eller 14 ugers dyrkning øger en ekspression af et gen af interesse med mindst 10 %, mindst 20 %, mindst 30 %, mindst 40 %, mindst 50 %, mindst 60 % eller mindst 70 %.
9. Rekombinant pattedyrcelle omfattende højst 20, 15, 10 eller 5 rekombinante nukleinsyremolekyler ifølge krav 1 eller 2, fortrinsvis integreret i cellens genom som enkelte kopier.
10. Rekombinant pattedyrcelle omfattende: a) en nukleinsyre ifølge krav 1, hvor nukleinsyren er integreret i pattedyrcellens genom, og b) et rekombinant nukleinsyremolekyle omfattende: (i) mindst ét transgen af interesse og (ii) et MAR-element, hvor MAR-elementet er udvalgt fra SEQ ID NO: 1 (MAR 1-68), 2 (MAR 1_6), 3 (MAR X_S29), 4 (MAR S4), 5 (hønselysozym-MAR), eller er et konstrueret, delvis omarrangeret modstykke, der har mindst 80 %, 90 %, 95 %, 98 %, 99 % eller 100 % sekvensidentitet med en hvilken som helst af SEQ ID NO: 1 til 5.
11. Fremgangsmåde til transfektion in vitro af pattedyrceller, særligt hamsterceller, omfattende: transfektion, eventuelt i en første transfektion, af pattedyrcellerne med mindst ét, mindst to, mindst tre eller mindst fire rekombinante nukleinsyremolekyler ifølge krav 1 eller 2.
12. Fremgangsmåde til transfektion in vitro af pattedyrceller ifølge krav 11, der endvidere omfatter: mindst én, mindst to, mindst tre eller mindst fire isolerede TEP (transgene expression processing)-funktionelle RNA og mindst ét transgen, som eventuelt er en del af et rekombinant nukleinsyremolekyle, som eventuelt er transficeret i en anden efterfølgende transfektion, eventuelt sammen med en isoleret nukleinsyre eller mRNA, der udtrykker en transposase, som genkender 5' og 3' ITR'ene.
13. Kit omfattende i en beholder mindst én vektor, der omfatter et rekombinant nukleinsyremolekyle ifølge krav 1 eller 2 og i en anden eventuel beholder en vektor, der koder for en kompatibel transposase og i en yderligere beholder anvisning i at anvende vektoren eller vektorerne.
14. Anvendelse in vitro af en rekombinant nukleinsyre ifølge krav 1 eller 2 og/eller en rekombinant pattedyrcelle ifølge krav 10 eller 11 til forøgelse af transgenintegration og/eller -ekspression.
DK14708935.3T 2013-02-01 2014-02-01 Forøget transgenekspression og -processering DK2951309T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361759802P 2013-02-01 2013-02-01
US201361800244P 2013-03-15 2013-03-15
US201361806634P 2013-03-29 2013-03-29
PCT/IB2014/000100 WO2014118619A2 (en) 2013-02-01 2014-02-01 Enhanced transgene expression and processing

Publications (1)

Publication Number Publication Date
DK2951309T3 true DK2951309T3 (da) 2019-04-23

Family

ID=50239688

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14708935.3T DK2951309T3 (da) 2013-02-01 2014-02-01 Forøget transgenekspression og -processering
DK19153376.9T DK3536797T3 (da) 2013-02-01 2014-02-01 Forhøjet transgenudtrykkelse og -forarbejdning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19153376.9T DK3536797T3 (da) 2013-02-01 2014-02-01 Forhøjet transgenudtrykkelse og -forarbejdning

Country Status (21)

Country Link
US (1) US11898154B2 (da)
EP (2) EP3536797B1 (da)
JP (1) JP6563816B2 (da)
KR (1) KR102235603B1 (da)
CN (1) CN105073995A (da)
AU (2) AU2014210856B2 (da)
CA (1) CA2898878C (da)
DK (2) DK2951309T3 (da)
ES (2) ES2940433T3 (da)
FI (1) FI3536797T3 (da)
HK (1) HK1216323A1 (da)
HU (2) HUE061494T2 (da)
IL (1) IL240198B (da)
LT (1) LT2951309T (da)
PL (2) PL3536797T3 (da)
PT (2) PT2951309T (da)
RU (1) RU2711505C9 (da)
SG (2) SG10201803758XA (da)
SI (1) SI2951309T1 (da)
WO (1) WO2014118619A2 (da)
ZA (1) ZA201506419B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109576269B (zh) * 2014-04-01 2020-08-28 三生国健药业(上海)股份有限公司 一种含mar核心片段的动物细胞表达载体
CN105154473B (zh) * 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
JP6871679B2 (ja) * 2016-03-23 2021-05-12 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
US20180265894A1 (en) * 2015-10-06 2018-09-20 National University Corporation Okayama University Gene Expression Cassette And Product Thereof
JP2017070224A (ja) * 2015-10-06 2017-04-13 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
AU2016375159B2 (en) 2015-12-24 2022-12-15 Selexis S.A. Improved eukaryotic cells for protein manufacturing and methods of making them
ITUA20161610A1 (it) * 2016-03-14 2017-09-14 Angela Anna Messina Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
EP3219803A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum für Molekulare Medizin Enhanced sleeping beauty transposons, kits and methods of transposition
EP3219800A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
KR102536221B1 (ko) * 2016-05-03 2023-05-23 론자 리미티드 단백질 생산을 위한 지질 대사의 조정
SG10201912370RA (en) * 2016-10-03 2020-02-27 Daiichi Sankyo Co Ltd PROMOTER OF Hspa5 GENE
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
EP3555273B1 (en) 2016-12-16 2024-05-22 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
WO2018224162A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for characterizing loss of antigen presentation
CN111465697B (zh) * 2017-09-29 2023-10-13 贝特基因 用于预防或治疗心力衰竭的药物组合物
CN109929839B (zh) * 2017-12-18 2021-02-12 华东师范大学 拆分型单碱基基因编辑系统及其应用
CN108504692B (zh) * 2018-03-26 2021-07-23 安徽大学 一种基因敲除cho细胞株的构建方法及其在治疗性重组蛋白表达中的应用
WO2019219947A1 (en) * 2018-05-18 2019-11-21 Sorbonne Universite Molecular tools and methods for transgene integration and their transposition dependent expression
CA3104288A1 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
RU2686102C1 (ru) * 2018-08-07 2019-04-24 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Рекомбинантный вектор для создания плазмидных генетических конструкций, обладающих повышенной длительностью экспрессии целевых генов
WO2020049106A1 (en) * 2018-09-05 2020-03-12 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft A method for engineering synthetic cis-regulatory dna
US20210380661A1 (en) * 2018-10-16 2021-12-09 Texas Tech University System Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes
WO2020084528A1 (en) 2018-10-24 2020-04-30 Selexis Sa Expression systems, recombinant cells and uses thereof
WO2020136149A1 (en) * 2018-12-24 2020-07-02 Selexis Sa Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells
WO2020152532A1 (en) 2019-01-23 2020-07-30 Enzyvant Therapeutics Gmbh Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
IT201900002321A1 (it) * 2019-02-18 2020-08-18 Univ Degli Studi Padova Peptidi con attivita' antitumorale
US20220177546A1 (en) * 2019-03-27 2022-06-09 Phoenix Tissue Repair, Inc. Systems and methods for producing collagen 7 compositions
CN110006866B (zh) * 2019-04-16 2022-04-22 杭州迈尔德生物科技有限公司 一种阿片类活性物质的通用检测方法及其检测试剂盒
WO2020228721A1 (en) * 2019-05-13 2020-11-19 Lin Mei Chun Method and kit for monitoring cancer
CA3154452A1 (en) * 2019-10-10 2021-04-15 The Regents Of The University Of California Methods to stabilize mammalian cells
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
CN110863008B (zh) * 2019-11-22 2020-10-16 昆明学院 Mar序列调控弱启动子构建高效表达载体的方法
EP4058467A1 (en) 2019-12-24 2022-09-21 Selexis SA Targeted integration in mammalian sequences enhancing gene expression
EP4107272A2 (en) * 2020-02-19 2022-12-28 Wuxi Biologics Ireland Limited Enhanced expression system and methods of use thereof
CN111500629B (zh) * 2020-04-17 2021-11-19 安徽中盛溯源生物科技有限公司 一种高表达层粘连蛋白-511变体的方法及其应用
US20230242936A1 (en) * 2020-05-14 2023-08-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Dual promoter systems
US20220010332A1 (en) * 2020-07-08 2022-01-13 Neuracle Genetics Inc. Intron fragments
CN113881703B (zh) * 2021-10-11 2022-06-21 中国人民解放军军事科学院军事医学研究院 一种提高cho细胞同源重组效率的方法及其相关产品和应用
CN116440269B (zh) * 2022-01-10 2024-02-09 华中农业大学 Slc35a1基因作为靶点在防治猪流行性腹泻病中的应用
CN114958914B (zh) * 2022-06-06 2023-09-26 新乡医学院 一种人类及哺乳动物细胞附着体表达载体、构建方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731178A (en) 1990-03-21 1998-03-24 Behringwerke Aktiengesellschaft Attachment-elements for stimulation of eukaryotic expression systems
JP3656277B2 (ja) * 1995-05-17 2005-06-08 味の素株式会社 組換えdna法によるトランスグルタミナーゼの効率的製造法
EP1395669B1 (en) * 2001-01-26 2009-07-22 Selexis S.A. Matrix attachment regions and methods for use thereof
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
WO2004065581A2 (en) * 2003-01-15 2004-08-05 Discovery Genomics, Inc. Transposon-insulator element delivery systems
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
IN2014DN02483A (da) 2003-10-24 2015-05-15 Selexis Sa
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
MX2007015540A (es) 2005-06-10 2008-03-07 Genentech Inc Mejora de la expresion de anticuerpos utilizando vectores que contienen elementos aislantes.
DK3156414T3 (da) 2007-09-26 2020-03-09 Intrexon Corp Syntetisk 5'utrs ekspressionsvektorer og fremgangsmåder til øgning af transgen ekspression
US20090247609A1 (en) 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
US20100105140A1 (en) * 2008-07-16 2010-04-29 Fahrenkrug Scott C Plaice dna transposon system
EP2417263B1 (en) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors
CA2774470A1 (en) * 2009-09-18 2011-03-24 Selexis S.A. Products and methods for enhanced transgene expression and processing

Also Published As

Publication number Publication date
WO2014118619A2 (en) 2014-08-07
EP2951309A2 (en) 2015-12-09
AU2014210856A1 (en) 2015-07-30
US20150361451A1 (en) 2015-12-17
KR102235603B1 (ko) 2021-04-05
PL2951309T3 (pl) 2019-06-28
HUE061494T2 (hu) 2023-07-28
RU2711505C9 (ru) 2020-08-12
IL240198B (en) 2019-10-31
LT2951309T (lt) 2019-03-25
AU2014210856B2 (en) 2019-10-24
ES2717175T3 (es) 2019-06-19
ZA201506419B (en) 2017-02-22
EP3536797A1 (en) 2019-09-11
CN105073995A (zh) 2015-11-18
RU2015127667A (ru) 2017-03-06
PT2951309T (pt) 2019-04-03
FI3536797T3 (fi) 2023-03-23
HUE043103T2 (hu) 2019-08-28
EP2951309B1 (en) 2019-01-30
HK1216323A1 (zh) 2016-11-04
CA2898878C (en) 2020-04-28
EP3536797B1 (en) 2023-01-04
PT3536797T (pt) 2023-03-15
SI2951309T1 (sl) 2019-04-30
KR20150123803A (ko) 2015-11-04
AU2019250224A1 (en) 2019-11-07
AU2019250224B2 (en) 2022-05-12
PL3536797T3 (pl) 2023-09-11
IL240198A0 (en) 2015-09-24
ES2940433T3 (es) 2023-05-08
SG10201803758XA (en) 2018-06-28
JP2016504922A (ja) 2016-02-18
US11898154B2 (en) 2024-02-13
SG11201505487UA (en) 2015-08-28
RU2711505C2 (ru) 2020-01-17
CA2898878A1 (en) 2014-08-07
JP6563816B2 (ja) 2019-08-21
WO2014118619A3 (en) 2014-10-30
DK3536797T3 (da) 2023-04-03

Similar Documents

Publication Publication Date Title
AU2019250224B2 (en) Enhanced transgene expression and processing
AU2022201329B2 (en) Genetically modified cells, tissues, and organs for treating disease
KR102301464B1 (ko) 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
KR20210149060A (ko) Tn7-유사 트랜스포존을 사용한 rna-유도된 dna 통합
KR20200058508A (ko) 게놈 편집을 위한 폴리뉴클레오티드, 조성물 및 방법
KR20120099376A (ko) 강화된 전이 유전자 발현과 공정 방법 및 그 산물
KR20220002609A (ko) 포유동물 세포의 특성을 변경하기 위한 인공 마이크로-rna 및 이들 생성물의 조성물을 사용한 포유동물 세포의 변형
KR101476010B1 (ko) 고생산성 세포의 수립을 위한 발현 벡터 및 고생산성 세포
KR20200126997A (ko) 인간 대상체에서의 비-노화-관련 청각 손상의 치료를 위한 조성물 및 방법
KR20210143897A (ko) 오리지아스로부터의 트랜스포사제를 이용한 핵산 작제물의 진핵세포로의 통합
KR102531749B1 (ko) Cho 세포 내 통합 부위
AU2022200903B2 (en) Engineered Cascade components and Cascade complexes
KR20210144861A (ko) 아마이엘로이스로부터의 트랜스포사제를 이용한 핵산 작제물의 진핵세포 게놈으로의 전위
KR20210060429A (ko) 적응 면역의 조절을 위한 조성물 및 방법
KR20230129996A (ko) 탈아미노화를 포함하는 게놈 편집을 위한 폴리뉴클레오타이드,조성물 및 방법
RU2752529C9 (ru) Улучшенные эукариотические клетки для получения белка и способы их получения
CN113544257A (zh) 中国仓鼠卵巢细胞中内源性逆转录病毒的表征及灭活
KR20220157944A (ko) 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
TW201207103A (en) DNA element having the activity of enhancing foreign gene expression
CN115279910A (zh) 可调转座子系统
CN109790539A (zh) Hspa5基因的启动子
RU2774631C1 (ru) Сконструированные компоненты cascade и комплексы cascade
RU2814721C2 (ru) Транспозиция конструкций нуклеиновой кислоты в эукариотические геномы с транспозазой из amyelois
RU2817770C2 (ru) Интеграция конструкций нуклеиновой кислоты в эукариотические клетки с транспозазой из oryzias
NL2027815B1 (en) Genomic integration